A double blind, placebo controlled study to investigate the role of NMDA [n-methyl-d-aspartic acid] receptor NR2B subunit selective antagonism on cognitive functions and neurophysiology in healthy subjects as measured with MRI [magnetic resonance imaging]

Trial Profile

A double blind, placebo controlled study to investigate the role of NMDA [n-methyl-d-aspartic acid] receptor NR2B subunit selective antagonism on cognitive functions and neurophysiology in healthy subjects as measured with MRI [magnetic resonance imaging]

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs EVT 101 (Primary)
  • Indications Alzheimer's disease; Depression; Neuropathic pain; Parkinson's disease
  • Focus Pharmacodynamics
  • Sponsors Evotec NeuroSciences
  • Most Recent Events

    • 28 Mar 2008 Interim results reported in an Evotec AG media release.
    • 08 Jan 2008 Status changed from in progress to completed.
    • 15 Nov 2007 Richmond Pharmacology added as trial centre.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top